Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the ...

Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...

Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.

Merck (MRK) anticipates full-year 2025 sales to be between $64.1B-$65.6B, including a negative impact of foreign exchange of approximately 2% ...

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Quarterly Gardasil sales of $1.55 billion missed Wall Street's estimates of around $1.8 billion, which has been pared back nearly 20% since the issues in China were disclosed last summer.

The drugmaker plans to temporarily pause shipments of its Gardasil vaccine to China at least through the middle of the year. Chairman and CEO Robert Davis told analysts the pause will help pare ...